^
    1d
    interACT: A multicenter, multicohort, phase 2 platform trial to personalize second-line treatment intensity and targeting in HR-positive, HER2-negative metastatic breast cancer through an integrated liquid biopsy algorithm. (2025-523460-21-00)
    P1/2, N=159, Not yet recruiting, Centro Di Riferimento Oncologico Di Aviano
    New P1/2 trial • Liquid biopsy
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • fulvestrant • Truqap (capivasertib) • Orserdu (elacestrant)
    6d
    CAPItrue: Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients (clinicaltrials.gov)
    P3, N=258, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor) • PTEN (Phosphatase and tensin homolog) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CD4 (CD4 Molecule)
    |
    HER-2 negative • PGR positive
    |
    fulvestrant • Truqap (capivasertib)
    12d
    Precision: Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib (clinicaltrials.gov)
    P1/2, N=53, Not yet recruiting, Shanxi Province Cancer Hospital
    New P1/2 trial • First-in-human
    |
    PD-L1 (Programmed death ligand 1) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD4 (CD4 Molecule)
    |
    EGFR mutation • PIK3CA mutation • EGFR L858R • EGFR exon 19 deletion • AKT1 mutation
    |
    Tagrisso (osimertinib) • Truqap (capivasertib)
    18d
    Targeted therapy for DNA damage response and homologous recombination repair defects: The Olaparib Combinations trial. (PubMed, Cancer)
    The study failed to meet its primary end point of ORR. DDR and homologous recombination repair defects are not consistently actionable with olaparib as monotherapy or in combination with other targeted therapies in a histology-agnostic manner.
    Journal • PARP Biomarker
    |
    HRD (Homologous Recombination Deficiency) • ARID1A (AT-rich interaction domain 1A)
    |
    ARID1A mutation
    |
    Lynparza (olaparib) • Truqap (capivasertib) • ceralasertib (AZD6738)
    18d
    A Computational Strategy to Identify Hub Genes in Pathway Analysis of Gamma Tocotrienol-treated MCF-7 Cells and Molecular Docking Study Using Selected Phytochemicals as Therapeutic Agents. (PubMed, Curr Med Chem)
    These findings may facilitate the development of traditional medicinebased therapeutic strategies and provide insights for potential lead optimization in breast cancer drug discovery.
    Journal
    |
    EGR1 (Early Growth Response 1)
    |
    Piqray (alpelisib) • Truqap (capivasertib) • Orserdu (elacestrant) • Legalon (silibinin)
    20d
    GARD: Genomic Data-Based Drug Repurposing in Head and Neck Cancer with Large Language Model Validation. (PubMed, Cancers (Basel))
    Drug-gene mapping revealed candidates spanning those already in clinical trials for HNC (e.g., Afatinib, Cabozantinib, Dasatinib, Brigatinib, Lenvatinib, Capivasertib, and Erdafitinib) and emerging or repurposing candidates (Amuvatinib, XL765 (Voxtalisib), Golotimod, Artenimol, Quercetin, and Acetylsalicylic Acid), offering opportunities for precision repurposing...HPV stratification enhances precision, literature-based validation strengthens confidence, and integrated drug mapping enables refinement of existing therapies and discovery of novel candidates for personalized treatment strategies. Code Availability: The full implementation of the GARD pipeline, including preprocessing scripts, statistical analysis modules, and visualization tools, is publicly available on GitHub.
    Journal • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • SOX2 • CLDN1 (Claudin 1) • TLR7 (Toll Like Receptor 7) • EIF4G1 (Eukaryotic translation initiation factor 4 gamma, 1)
    |
    Gilotrif (afatinib) • dasatinib • Lenvima (lenvatinib) • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Alunbrig (brigatinib) • Truqap (capivasertib) • amuvatinib (MP470) • aspirin • voxtalisib (SAR245409)
    24d
    NRG-GY012: Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone (clinicaltrials.gov)
    P2, N=288, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Jan 2027
    Trial completion date
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • Truqap (capivasertib) • Recentin (cediranib)
    26d
    Neutrophil extracellular trap-related genes in PTCL: identification, prognosis and drug interaction prediction via bioinformatics-machine learning. (PubMed, Hematology)
    Potential therapeutic agents (e.g. capivasertib, lenalidomide) were predicted, and lenalidomide may represent a feasible initial treatment option for PTCL, with an objective response rate (ORR) of 40.0% and a maximum survival duration exceeding 50 months. NET-RGs play crucial roles in diagnosis, prognosis, and TME regulation, and lenalidomide, a putative TNF-targeting agent, may represent a feasible initial treatment option in PTCL.
    Journal
    |
    AKT2 (V-akt murine thymoma viral oncogene homolog 2) • IRF1 (Interferon Regulatory Factor 1) • MAPK14 (Mitogen-Activated Protein Kinase 14)
    |
    lenalidomide • Truqap (capivasertib)
    27d
    Capivasertib combines with trastuzumab deruxtecan to enhance anti-tumour activity in HER2-positive and HER2-low tumours. (PubMed, Mol Cancer Ther)
    In cell lines sensitive to the combination, combining T-DXd with capivasertib targeted complimentary pathways which resulted in disruption of the cell cycle and increased cell death. These results suggest that T-DXd combined with capivasertib has the potential to be active in HER2-positive as well as HER2-low tumours independent of PI3K pathway alteration status.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog)
    |
    HER-2 positive • HER-2 negative • HER-2 expression • HER-2 underexpression
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • Truqap (capivasertib)
    29d
    CAVALRY: CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL (clinicaltrials.gov)
    P1/2, N=104, Recruiting, University of Chicago | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • cytarabine • cyclophosphamide • Blincyto (blinatumomab) • Truqap (capivasertib) • nelarabine
    1m
    A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Rosuvastatin in Healthy Participants (clinicaltrials.gov)
    P1, N=20, Completed, AstraZeneca | Recruiting --> Completed
    Trial completion
    |
    Truqap (capivasertib)